Jinekolojik Kanser Kontrolü ve Hemşirelik

Year 2014, Volume: 1 Issue: 2, 77 - 90, 27.11.2015

Kafiye Eroğlu , Gülten Koç

Abstract

Kanser ile ilgili son veriler, hem dünyada hem de ülkemizde jinekolojik kanserlerin insidans ve mortalite açısından ilk on kanser türü içinde yer aldığını göstermektedir. Jinekolojik kanserler tedavinin manevi ve maddi yükünün fazlalığı ile diğer kanserlerden farklıdır. Bu nedenle jinekolojik kanser mortalite ve morbiditesinin azaltılmasında kanser kontrolüne yönelik geliştirilmiş stratejiler daha da önem kazanmaktadır. Hemşireler kanser kontrolünün her aşamasında önemli rolleri olan sağlık çalışanlarıdır. Kanser kontrolünde hemşire kanseri önleme, tarama ve tanılamada danışmanlık yapma, bakım verme, sağlık eğitimi yapma, kanser vakalarını yönetme ve araştırma yapma rollerine sahiptir. Bu nedenle jinekolojik kanser ile ilişkili faktörleri bilerek kapsamlı bir tanılama, risk belirleme, genetik yatkınlık konularında analiz ve sentez yapabilecek bilgiye sahip olmalıdır. Böylece jinekolojik kanser gelişmesini önlemeye ve kansere bağlı ölümleri azaltmaya yönelik bireye özgü programlar geliştirebilir.

Anahtar kelimeler: Jinekolojik kanser, kanserden korunma, sağlığın geliştirilmesi, hemşirelik

Keywords

Jinekolojik kanser, kanserden korunma, sağlığın geliştirilmesi, hemşirelik

References

• 1. World Cancer Reports 2008. URL: http://www.iarc.fr/en/publications/pdfs-online/wcr. 28 Haziran 2013.
• 2. Dünya Kanser Bildirgesi 2008. URL: http://www.turkkanser.org.tr/newsfiles/145Dunya_Kanser_ Bildirgesi.pdf. 28 Haziran 2013.
• 3. GLOBOCAN 2008. URL: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900. 28 Haziran 2013.
• 4. Ergör G. Türkiye’de Bulaşıcı Olmayan Hastalıklar. Kanser Mortalitesi. Ed: Ünal B. HASUDER Türkiye Halk Sağlık Raporu. İzmir: 2012. s 286-287.
• 5. Cancer Prevention, Detection, and Control: A Nursing Perspective Overview: Section I. Fundamentals of Cancer Prevention, Detection, and Control. Mahon SM. URL: http://www.ons.org/Publications/ Books/Excerpts/INPU0525ovr. 28 Haziran 2013.
• 6. Counseling to Prevent Gynecologic Cancers. URL: http://www.odphp.osophs.dhhs.gov/pubs/guidecps/ PDF/CH64.PDF. 28 Haziran 2013.
• 7. 2008-2013 Action Plan; For the Global Strategy for the Prevention and Control of Noncommunicable Diseases, World Health Organization 2008, WHO Document Production Services, Geneva, Switzerland.
• 8. Giray H, Ünal B, Kanser epidemiyolojisi. Sağlık ve Toplum Dergisi. 2007; 17(3): 10-16.
• 9. ACS Guidelines on Nutrition and Physical Activity for Cancer Prevention, URL: http://www.cancer. org/healthy/eathealthygetactive/acsguidelinesonnutritionphysicalactivityforcancerprevention/nupaguidelines-toc. 28 Haziran 2013.
• 10. Türkiye Kanser İnsidansları 2004-2006, Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı, URL: http://www.kanser.gov.tr/index.php/daire-faaliyetleri/kanser-istatistikleri.html. 28 Haziran 2013.
• 11. Cancer Awareness Calendar 2013, URL: http://www.cancer.org/aboutus/whoweare/cancer-awarenesscalendar. 28 Haziran 2013.
• 12. Somer A. Humanpapilloma virüs aşıları, J Pediatr Inf. 2008; 2 (Suppl 2): 50-55.
• 13. CDC 2007. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee for Immunization Practices (ACIP). MMWR; 56(No. RR-2).
• 14. Food and Drug Administration. 2009. Product approval-prescribing information Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant]. URL: http://www.fda.gov/ biologicsbloodvaccines/vaccines/approvedproducts/ucm094042.htm. 28 Haziran 2013.
• 15. Comprehensıve Cervical Cancer Control; A Guide To Essential Practice, World Health Organization. 2006. WHO Document Production Services, Geneva, Switzerland.
• 16. Peters RK, Duncan T, Donald GH, Thomas MM, Henderson BE, Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. J Natl Cancer Inst.1986; 77:1063–1077.
• 17. Parazzini F, Negri E, La Vecchia C, Fedele L. Barrier methods of contraception and the risk of cervical neoplasia. Contraception. 1989; 40:519–530.
• 18. Slattery ML, Overall JC, Abbott TM, French TK, Robison LM, Gardner J. Sexual activity, contraception, genital infections, and cervical cancer: support for a sexually transmitted disease hypothesis. Am J Epidemiol. 1989; 130:248–258.
• 19. American Cancer Society Guidelines for the Early Detection of Cancer. 2013. URL: http://www.cancer. org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-theearly-detection-of-cancer. 28 Haziran 2013.
• 20. Cervical Cancer Screening in Developing Countries, Report of a WHO Consultation. 2002. WHO Publications, France.
• 21. Serviks Kanseri Tarama Programı Ulusal Standartları, Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı. URL: http://thsk.gov.tr/tr/index.php/kanser-nedir/425-serviks-kanser-standartlari. 28 Haziran 2013.
• 22. American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer With Healthy Food Choices and Physical Activity CA Cancer J Clin. 2006; 56:254–281.
• 23. Fairfield KM, Hankinson SE, Rosner BA, Hunter DJ, Colditz GA, Willett WC. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids. Cancer. 2001; 92:2318-2325.
• 24. Cust AE. Physical activity and gynecologic cancer prevention. Recent Results in Cancer Research. 2011; 186:159-185.
• 25. Gross TP, Sehlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gyneeol. 1994; 83:419-424.
• 26. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998; 339:424-428.
• 27. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and nonearriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345(4):235-240.
• 28. Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncology. 2000; 18(9):1980-1995.
• 29. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations:A case-control study. Lancet. 2001; 357(9267):1457- 1470.
• 30. Khurana PS, Khurana C, Hsia J. HRT for prevention of coronary heart disease: Current evidence. Curr Atheroseler Rep. 2001; 3:399-403.
• 31. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospeetire study of US women. JAMA. 2001; 285(11):1460-1465.
• 32. Cherry C., Vacchıano SA. Ovarian Cancer Screening and Prevention, Seminars in Oncology Nursing, 2002; 18(3):167-173.
• 33. National Institutes of Health Consensus Development Conference Statement. 1994. Gynecol Oncol. 55:4-14.
• 34. National Comprehensive Cancer Network practice guidelines: 1999 Genetics/familial high-risk cancer screening. Oncology 13:161-183.
• 35. Ries LAG, Eisner MP and Kosary CL. SEER Cancer Statistics Review: 1973-1998, National Cancer Institute. 2001. URL: http://seer.cancer.gov/csr/1973_1998/. 28 Haziran 2013.
• 36. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Javalieri RJ et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review. Gastroenterology. 2003; 104(5):1535-1549.
• 37. Boyd J, Rubin SC. Hereditary ovarian cancer: Molecular genetics and clinical implications. Gynecol Oncol. 1997; 64(2):196-206
• 38. Sonoda Y, Barakat RR. Screening and the prevention of gynecologic cancer: Endometrial cancer, Best Practice & Research Clinical Obstetrics and Gynaecology. 2006; 20(2):363-377.
• 39. Herbst AL. OCs and genital tract malignancies. Dialogues Contracept. 1994; 4(3): 5–7.
• 40. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes and Control. 1999; 10(4): 277–284.
• 41. Parazzini F, La Vecchia C, Negri E, Moroni S, Chatenoud L. Smoking and risk of endometrial cancer: results from an Italian case-control study. Gynecologic Oncology. 1995; 56(2): 195–199.
• 42. Newcomer LM, Newcomb PA, Trentham-Dietz A, Storer BE. Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes and Control. 2001; 12(9): 829–835.
• 43. Viswanathan AN, Feskanich D, De Vivo I, Hunter DJ, Barbieri RL, Rosner B, et al. Smoking and the risk of endometrial cancer: results from the nurses’ health study. International Journal of Cancer. 2005; 114(6): 996–1001.
• 44. Anderson GL, Judd HL, Kaunitz AM (2003) Women’s health initiative investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women’s health initiative randomized trial. The Journal of the American Medical Association. 2003; 290(13):1739–1748
• 45. Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. American Journal of Epidemiology. 1998; 148(3): 234–240.
• 46. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women’s Health Study. American Journal of Epidemiology 1996; 143(12): 1195–1202.
• 47. Xu WH, Xiang YB, Ruan ZX, Zeng W, Cheng JR, Dai Q, et al. Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai. International Journal of Cancer 2004; 108(4): 613–619.
• 48. Wickerham DL, Fisher B, Wolmark N, Bryant J, Association of tamoxifen and uterine sarcoma. Journal of Clinical Oncology 2002; 20(11): 2758–2760.
• 49. Swanson CA, et al.. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiology Biomarkers and Prevention 1993; 2:321–327.
• 50. Calle EE, Rodriguez C,Walker-Thurmond K & Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. The New England Journal of Medicine 2003; 348(17): 1625–1638.
• 51. Macdonald D. The Oncology Nurse’s Role in Cancer Risk Assessment and Counseling, Semin Oncol Nurse. 1997; 13(2):123-8.
• 52. Turkistanlı EC, Sogukpınar N, Saydam BK, Aydemir G.Cervical cancer prevention and early detection - the role of nurses and midwives. Asian Pacific Journal of Cancer Prevention. 2003; 4(1):15-21.
• 53. Oncology Nurse. URL: http://www.nursesource.org/oncology.html. 28 Haziran 2013.